spacer
home > ict > summer 2018 > pro translation
PUBLICATIONS
International Clinical Trials

PRO Translation

The use of patient-reported outcomes (PROs) has grown considerably in the last several decades, spreading into new technologies and supporting the evaluation of endpoints in clinical trials and regulatory decision-making. With this growth in their use and impact comes an increased obligation to ensure PROs collect high-quality data, both in terms of properly defining the constructs that PROs intend to measure and ensuring that patients are able to comprehend their content despite typically low familiarity with PROs and the language they use compared to healthcare professionals. An analysis was conducted on the term ‘disease activity’ as used in four separate PROs. Through investigation of patients’ comprehension of this term and their reactions to its translation in a variety of languages and countries, suggestions can be drawn to improve the quality of data collected by PROs that assess disease activity.

Study Objective

The objective of the study was to identify terminology found in PROs that causes difficulty in translation and comprehension. Identifying such terminology and solutions that improve translation and patient comprehension is critical to increasing the validity of PROs and their treatment insights. As such, the use of the term ‘disease activity’ was investigated in PROs across 29 languages. Disease activity can be defined as “manifestations of a disease” and typically appears in instruments assessing the state of a patient’s disease signs and symptoms (1-2).

Previous translation projects have suggested that disease activity is frequently identified by patients as a problematic term. However, to date, a systematic analysis of instruments that use this term has not been conducted. Here, data is presented from several translation projects involving the term ‘disease activity’, illustrating the difficulties that patients face in interpreting the term, and ways to mitigate these difficulties through revised or expanded translations are proposed.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Tim Poepsel is a Survey Research Analyst with RWS Life Sciences. He has a BA in linguistics from Northwestern University, US, and a PhD in psychology and language science from Penn State University, US. Tim specialises in the area of linguistic validation, and his research focusses on the patient perspective in the development and administration of clinical outcome assessment (COA) instruments.

Barbaa Brandrt is Survey Research Analyst Team Lead at RWS Life Sciences. Barbara has 17 years of experience in COAs, linguistic validation, translatability assessment, and electronic COAs and usability testing. She has a BA in linguistics and psychology and an MA in Survey Research from the University of Connecticut, US.

Elizabeth Yohe Moore is the COA process development lead at RWS Life Sciences with eight years of healthcare industry experience. She received a BA in neuroscience and economics from Oberlin College, US, and an MPH from Northwestern University, US.

Elizabeth McCullough is the Manager of Linguistic Validation Services at RWS Life Sciences. Elizabeth has worked in the areas of medical translation and linguistic validation for 10 years. She holds an MA in translation from the Institute for Applied Linguistics at Kent State University, US.

Shawn McKown is the Senior Director and Practice Lead of Linguistic Validation at RWS Life Sciences. Shawn has worked with COAs, patient-reported outcomes, and linguistic validation within the clinical trial space for over 15 years and holds an MA from the University of Chicago, US.
spacer
Dr Tim Poepsel
spacer
spacer
spacer
Barbara Brandt
spacer
spacer
spacer
Elizabeth Yohe Moore
spacer
spacer
spacer
Elizabeth McCullough
spacer
spacer
spacer
Shawn McKown
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Genome & Company Chooses Luina Bio to Supply Innovative Drug Productfor Clinical Trials Programme

Luina Bio, a leading biopharmaceutical manufacturing company in Australia, today announced it will develop and produce an innovative bacterial drug product for Genome & Company to support its clinical trials programme. The relationship signals Luina Bio’s first foray into Asia and further establishes its global leadership in the current Good Manufacturing Practise for microbiome projects.
More info >>

White Papers
 
Industry Events

14th Annual Biomarkers Congress

21-22 February 2019, Manchester Central Convention Complex, UK

Oxford Global is proud to present for the 14th year our flagship Biomarkers Congress, taking place 21 – 22 February 2019 in Manchester, UK. An updated programme ensures you will benefit from talks on the latest strategies and technologies impacting growth in the biomarker industry.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement